Advances in Chronic Kidney Disease
Volume 17, Issue 1 , Pages 72-82 , January 2010

Antiretroviral Medications: Adverse Effects on the Kidney

  • Jennifer Jao
    • ,
  • Christina M. Wyatt

      Affiliations

    • Corresponding Author InformationAddress correspondence to Christina M. Wyatt, MD, Box 1243, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029.

References 

  1. UNAIDS 2008 Report on the Global AIDS epidemic. Available at: http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp. Accessed May 14, 2009
  2. El-Sadr WM, Lundgren JD, Neaton JD, et al. Strategies for management of Antiretroviral Therapy (SMART) Study Group: CD4 count–guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296
  3. Gupta S, Eustace J, Winston JA, et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2005;40:1559–1585
  4. Jung N, Lehmann C, Rubbert A, et al. Relevance of the organic cation transporters 1and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos. 2008;36:1616–1623
  5. Takeda M, Khamdang S, Narikawa S, et al. Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002;300:918–924
  6. Leung S, Bendayan R. Uptake properties of lamivudine (3TC) by a continuous renal epithelial cell line. Can J Physiol Pharmacol. 2001;79:59–66
  7. Cihlar R, Ho E, Lin D, et al. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001;20:641–648
  8. Uwai Y, Ida H, Tsuji Y, et al. Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res. 2007;24:811–815
  9. Nelson M, Azwa A, Sokwala A, et al. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy. AIDS. 2008;22:1374–1375
  10. Ahmad M. Abacavir-induced reversible Fanconi syndrome with nephrogenic diabetes insipidus in a patient with acquired immunodeficiency syndrome. J Postgrad Med. 2006;52:296–297
  11. Krishnan M, Nair R, Haas M, et al. Acute renal failure in an HIV positive 50 year old man. Am J Kidney Dis. 2000;36:1075–1078
  12. Crowther MA, Callaghan W, Hodsman A, et al. Dideoxyinosine-associated nephrotoxicity. AIDS. 1993;7:131–132
  13. Izzedine H, Launay-Vacher V, Deray G. Fanconi syndrome associated with didanosine therapy. AIDS. 2005;19:844–845
  14. D'Ythurbide G, Goujard C, Méchaï F, et al. Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: A case report and literature review. Nephrol Dial Transplant. 2007;22:3656–3659
  15. John M, Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis. 2002;15:23–29
  16. Lund KC, Peterson L, Wallace KB. Absence of a universal mechanism of mitochondrial toxicity by nucleoside analogs. Antimicrob Agents Chemother. 2007;51:2531–2539
  17. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV cohort Study. Clin Infect Dis. 2001;33:1931–1937
  18. Ray A, Cihlar T, Robinson K, et al. Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother. 2006;50:3297–3304
  19. Van Rompay KK, Brignolo LL, Meyer DJ, et al. Biological effects of short-term or prolonged administration of tenofovir to newborn and infant rhesus macaques. Antimicrob Agents Chemother. 2004;48:1469–1487
  20. Gitman M, Hirschwerk D, Baskin C, et al. Tenofovir-induced kidney injury. Expert Opin Drug Saf. 2007;6:155–164
  21. Gupta S. Tenofovir-associated Fanconi syndrome: review of the FDA Adverse Event Reporting System. AIDS Patient Care STDS. 2008;22:99–103
  22. Kearney BP, Sayre JR, Flaherty JF, et al. Drug-drug and drug-food interactions between tenofovir disoproxil fumarate and didanosine. J Clin Pharmacol. 2005;45:1360–1367
  23. Kearney BP, Mathias A, Mittan A, et al. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006;43:278–283
  24. Zimmerman A, Pizzoferrato T, Bedford J, et al. Tenofovir-associated acute and chronic kidney disease: A case of multiple drug interactions. Clin Infect Dis. 2006;42:283–290
  25. Gallant J, Parish M, Keruly J, et al. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis. 2005;40:1194–1198
  26. Winston A, Amin J, Mallon P, et al. Minor changes in calculated creatinine clearance and anion-gap are asoociated with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy. HIV Med. 2006;7:105–111
  27. Fux C, Simcock M, Wolbers M, et al. Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study. Antivir Ther. 2007;12:1165–1173
  28. Young B, Buchacz K, Baker R, et al. Renal function in tenofovir-exposed and tenofovir-unexposed patients receiving highly active antiretroviral therapy in the HIV outpatient study. J Int Assoc Physicians AIDS Care. 2007;6:178–187
  29. Barbour TD, Furlong TJ, Finlayson RJ. Efavirenz-associated podocyte damage. AIDS. 2007;21:257–258
  30. Wirth GJ, Teuscher J, Graf JD, et al. Efavirenz-induced urolithiasis. Urol Res. 2006;34:288–289
  31. Izzedine H, Valantin MA, Daudon M, et al. Efavirenz urolithiasis. AIDS. 2007;21:1992
  32. Angel-Moreno-Maroto A, Suarez-Castellano L, Hernandez-Cabrera M, et al. Severe efavirenz-induced hypersensitivity syndrome (not DRESS) with acute renal failure. J Infect. 2006;52:e39–e40
  33. Curry E, Thomas M, Yehia M. Renal impairment and hypersensitivity reaction due to efavirenz. Nephrology. 2008;13:541
  34. Knudtson E, Para M, Boswell H, et al. Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus. Obstet Gynecol. 2003;101:1094–1097
  35. Madruga J, Cahn P, Grinsztejn B, et al. Efficacy and safety of TMC125 (etravirine)in treatment-experienced HIV-1-infected patients in DUET-1: 24 week results from a randomized, double-blind, placebo-controlled trial. Lancet. 2007;370:29–38
  36. Lazzarin A, Campbell T, Clotet B, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24 week results from a randomized, double-blind, placebo-controlled trial. Lancet. 2007;370:39–47
  37. Duong M, Sgro C, Grappin M, et al. Renal failure after treatment with ritonavir. Lancet. 1996;348:693
  38. Stricker RB, Man KM, Bouvier DB, et al. Pancreatorenal syndrome associated with combination antiretroviral therapy in HIV infection. Lancet. 1997;349:1745–1746
  39. Engeler DS, John H, Rentsch KM, et al. Nelfinavir urinary stones. J Urol. 2002;167:1384–1385
  40. Feicke A, Rentsch K, Oertle D, et al. Same patient, new stone composition: Amprenavir urinary stone. Antivir Ther. 2008;13:733–734
  41. Green ST, McKendrick MW, Schmid ML, et al. Renal calculi developing de novo in a patients taking saquinavir. Int J STD AIDS. 1998;9:555–958
  42. Doco-Lecompte T, Garrec A, Thomas L, et al. Lopinavir/ritonavir (Kaletra) and lithiasis: seven cases. AIDS. 2004;18:705–706
  43. Gagnon R, Tecimer S, Watters A, et al. Prospective study of urinalysis abnormalities in HIV-positive individuals treated with indinavir. Am J Kidney Dis. 2000;36:507–515
  44. Kopp J, Miller K, Mican J, et al. Crystalluria and urinary tract abnormalities associated with indinavir. Ann Intern Med. 1997;127:119–125
  45. Balani S, Arison B, Mathai L, et al. Metabolites of L-735,524, a potent HIV-1 protease inhibitor, in human urine. Drug Metab Dispos. 1995;23:266–270
  46. Dieleman J, Sturkenboom M, Jambroes M, et al. Risk factors for the urological symptoms in a cohort of users of the HIV protease inhibitor indinavir sulfate: The ATHENA cohort. Arch Intern Med. 2002;162:1493–1501
  47. Sarcletti M, Petter A, Romani N, et al. Pyuria in patients treated with indinavir is associated with renal dysfunction. Clin Nephrol. 2000;54:261–270
  48. Van Rossum A, Dieleman J, Fraaij P, et al. Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir. Pediatrics. 2002;110:1–7
  49. Kopp J, Falloon J, Filie A, et al. Indinavir-associated interstitial nephritis and urothelial inflammation: clinical and cytologic findings. Clin Infect Dis. 2002;99:1122–1128
  50. Dieleman J, van der Feltz M, Bangma CH, et al. Papillary necrosis associated with the HIV protease inhibitor indinavir. Infection. 2001;29:232–233
  51. Iba-Ba J, Yombi J, Danse E, et al. Nécrose papillaire bilatérale lors d'un traitement par indinavir. Presse Med. 2008;37:967–969
  52. Hanabusa H, Tagami H, Hataya H. Renal atrophy associated with long-term treatment with indinavir. N Engl J Med. 1999;340:392–393
  53. Reyataz . Product information. Princeton, NJ: Bristol-Myers Squibb Company; June 2006;
  54. Chang H. Atazanavir urolithiasis. N Engl J Med. 2006;355:2158–2159
  55. Pacanowski J, Poirier JM, Petit I, et al. Atazanavir urinary stones in an HIV-infected patient. AIDS. 2006;20:2131
  56. Chan-Tack K, Truffa M, Struble K, et al. Atazanavir-associated nephrolithiasis: Cases from the US Food and Drug Administration's Adverse Event Reporting System. AIDS. 2007;21:1215–1218
  57. Couzigou C, Daudon M, Meynard J, et al. Urolithiasis in HIV-positive patients treated with atazanavir. Clin Infect Dis. 2007;45:e105–e108
  58. Brewster U, Perazella M. Acute interstitial nephritis associated with atazanavir, a new protease inhibitor. Am J Kidney Dis. 2004;44:e81–e84
  59. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses. 1993;9:1051–1053
  60. Tebas P, Bellos N, Lucasti C, et al. Enfuvirtide does not require dose adjustment in patients with chronic kidney failure. J Acquir Immune Defic Syndr. 2008;47:342–345
  61. Gulick R, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359:1429–1441
  62. Gulick R, Su Z, Flexner C, et al. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1 infected, treatment-experienced patients: AIDS Clinical Trials Group 5211. J Infect Dis. 2007;196:304–312
  63. Savarino A. A historical sketch of the discovery and development of HIV-1 integrase inhibitors. Expert Opin Investig Drugs. 2006;15:1507–1522
  64. Steigbigel R, Cooper D, Kumar P, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339–354
  65. DeJesus E, Berger D, Markowitz M, et al. Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr. 2006;43:1–5
  66. Zolopa AR, Mullen M, Berger D, et al: The HIV integrase inhibitor GS-9137 has potent antiretroviral activity in treatment-experienced patients [Oral Presentation 143LB]. Paper presented at: 14th Conference on Retroviruses and Opportunistic Infections. February 25-28, 2007, Los Angeles, CA
  67. Zolopa AR, Lampiris H, Blick G, et al. The HIV Integrase Inhibitor Elvitegravir (EVG/r) Has Potent and Durable Antiretroviral Activity in Treatment-Experienced Patients with Active Optimized Background Therapy (OBT) [Oral Presentation]. Paper presented at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 17-20, 2007, Chicago, IL
  68. Grinspoon S, Grunfeld C, Kotler D, et al. State of the Science Conference: Initiative to decrease cardiovascular risk and increase quality of care for patients living with HIV/AIDS Executive Summary. Circulation. 2008;118:198–210
  69. Friis-Møller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003
  70. Friis-Møller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723–1735
  71. D:A:D Study Group. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet. 2008;371:1417–1426
  72. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors amont patients with human immunodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506–2512
  73. Bozzette S, Ake C, Tam H, et al. Long-term survival and serious cardiovascular events in HIV-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47:338–341
  74. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1992;74:1045–1052
  75. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978–2982
  76. Kotler DP. HIV and antiretroviral therapy: Lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr. 2008;49:S79–S85
  77. Justman J, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003;32:298–302
  78. Brown T, Li X, Cole S, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS. 2005;19:1375–1383
  79. Moor MA, Flint O, Maa J, et al. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. AIDS. 2006;20:1813–1821
  80. Molina JM, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet. 2008;372:646–655
  81. Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet. 2007;370:49–58
  82. Gallant J, Staszewski S, Pozniak A, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients. JAMA. 2004;29:191–201
  83. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14:F63–F67
  84. Nolan K, Upton R, McKinnon E, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS. 2001;15:1275–1280
  85. Mondy K, Yarasheski K, Powderly W, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36:482–490
  86. Rivas P, Górgolas M, García-Delgado R, et al. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med. 2007;9:89–95
  87. Mora S, Zamproni I, Beccio S, et al. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab. 2004;89:24–28
  88. Giacomet V, Mora S, Martelli L, et al. A 12-month treatment with tenofovir does not impair bone mineral accrual in HIV-infected children. J Acquir Immune Defic Syndr. 2005;40:448–450
  89. Gafni R, Hazra R, Reynolds J, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Pediatrics. 2006;118:e711–e718
  90. Van Rompay K, Durand-Gasselin L, Brignolo L, et al. Chronic administration of tenofovir to rhesus macaques from infancy through adulthood and pregnancy: Summary of pharmacokinetics and biological and virological effects. Antimicrob Agents Chemother. 2008;52:3144–3160
  91. Sheehan MT, Wen SF. Hyperkalemic renal tubular acidosis induced by trimethoprim/sulfamethoxazole in an AIDS patient. Clin Nephrol. 1998;50:188–193
  92. Porras MC, Lecumberri JN, Castrillon J. Trimethoprim/sulfamethoxazole and metabolic acidosis in HIV-infected patients. Ann Pharmacother. 1998;32:185–189
  93. Velazquez H, Perazella M, Wright FS, et al. Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med. 1993;119:296–301
  94. Perazella MA, Mahnensmith RL. Trimethoprim-sulfamethoxazole: Hyperkalemia is an important complication regardless of dose. Clin Nephrol. 1996;46:187–192
  95. Alapan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfamethoxazole. Ann Intern Med. 1996;124:316–320
  96. Reiser I, Chou S, Brown M, et al. Reversal of trimethoprim-induced antikaliuresis. Kidney Int. 1996;50:2063–2069
  97. Perazella MA. Trimethoprim-induced hyperkalemia: Clinical data, mechanism, prevention, and management. Drug Saf. 2000;22:227–236
  98. De Vriese A, Robbrecht D, Vanholder R, et al. Rifampicin-associated acute renal failure: Pathophysiologic, immunologic, and clinical features. Am J Kidney Dis. 1998;31:108–115
  99. Covic A, Goldsmith D, Segall L, et al. Rifampicin-induced acute renal failure: A series of 60 patients. Nephrol Dial Transplant. 1998;13:924–929
  100. De Jager P, Van Altena R. Hearing loss and nephrotoxicity in longterm aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis. 2002;6:622–627
  101. Wingard JR, Kubilis P, Lee L, et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis. 1999;29:1402–1407
  102. Moreau P, Milpied N, Fayette N, et al. Reduced renal toxicity and improved clinical tolerance of amphotericin B mixed with intralipid compared with conventional amphotericin B in neutropenic patients. J Antimicrob Chemother. 1992;30:535–541
  103. Luber AD, Maa L, Lam M, et al. Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother. 1999;43:267–271
  104. Bates DW, Su L, Yu DT, et al. Correlates of acute renal failure in patients receiving parenteral amphotericin B. Kidney Int. 2001;60:1452–1459
  105. Becker BN, Fall P, Hall C, et al. Rapidly progressive acute renal failure due to acyclovir: A case report and review of the literature. Am J Kidney Dis. 1993;22:611–615
  106. De Miranda P, Blum MR. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983;12(suppl B):29–37
  107. Sawyer MH, Webb D, Balow J, et al. Acyclovir-induced renal failure. Am J Med. 1988;84:1067–1071
  108. Schmidt GM, Horak DA, Niland JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants: The City of Hope-Stanford-Syntex CMV Study Group. N Engl J Med. 1991;324:1005–1011
  109. Czock D, Scholle C, Rasche FM, et al. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin Pharmacol Ther. 2002;72:142–150
  110. Ljungman P, Deliliers G, Platzbecker U, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. Blood. 2001;97:388–392
  111. Lalezari JP, Holland G, Kramer F, et al. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr. 1998;17:339–344
  112. Polis M, Spooner K, Baird B, et al. Anticytomegaloviral activity and safety of cidofovir in patients in human immunodeficiency virus infection and cytomegalovirus viruria. Antimicrob Agents Chemother. 1995;39:882–886
  113. Cundy KC, Petty B, Flaherty J, et al. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1995;39:1247–1252
  114. Kahn J, Lagakos S, Wulfsohn M, et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial. JAMA. 1999;282:2305–2312
  115. Fisher E, Chaloner K, Cohn D, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: A randomized, placebo-controlled trial. AIDS. 2001;15:1695–1700
  116. Izzedine H, Hulot JS, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies. Kidney Int. 2004;66:1153–1158
  117. Ha NB, Ha NB, Garcia RT, et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology. 2009;Epub ahead of print
  118. Deray G, Martinez F, Katlama C, et al. Foscarnet nephrotoxicity: Mechanism, incidence and prevention. Am J Nephrol. 1989;9:316–321
  119. Jacobson MA. Review of the toxicities of foscarnet. J Acquir Immune Defic Syndr. 1992;5(suppl 1):S11–S17
  120. Maurice-Estepa L, Daudon M, Katlama C, et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis. 1998;32:392–400
  121. Navarro J, Quereda C, Quereda C, et al. Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Am J Kidney Dis. 1996;27:431–434
  122. Deray G, Katlama C, Dohin E. Prevention of foscarnet nephrotoxicity. Ann Intern Med. 1990;113:332

 Dr Wyatt has received research support from Gilead Sciences and from the Gilead Foundation.

PII: S1548-5595(09)00133-5

doi: 10.1053/j.ackd.2009.07.009

Advances in Chronic Kidney Disease
Volume 17, Issue 1 , Pages 72-82 , January 2010

Article Tools

* Image Usage & Resolution